On August 4, 2026, CFO J. Koning assured investors that the company would maintain its $882 million revenue guidance. By late October, however, management revised that figure to $862 million, citing lower biologics attachment rates, sluggish thoracolumbar procedure volumes, and international supply constraints. This latest adjustment places the company's annual outlook roughly $28 million below the $890 million forecast issued earlier in February.

Levi & Korsinsky is now evaluating potential violations of securities laws on behalf of shareholders who suffered financial losses. The inquiry focuses on whether the company’s previous statements regarding its fiscal health were materially misleading. Investors who purchased shares and incurred losses—regardless of whether they still hold the stock—are eligible for a confidential review of their positions. Legal representatives note that participants are not required to provide testimony or appear in court, as such matters typically proceed on a contingency basis.